Does the media favor RYTM or BNTX?

In the previous week, BioNTech had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 1 mentions for Rhythm Pharmaceuticals. BioNTech's average media sentiment score of 0.54 beat Rhythm Pharmaceuticals' score of 0.00 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSM or RYTM?

In the previous week, Insmed had 20 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 21 mentions for Insmed and 1 mentions for Rhythm Pharmaceuticals. Insmed's average media sentiment score of 0.84 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RYTM or ROIV?

In the previous week, Roivant Sciences had 10 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 11 mentions for Roivant Sciences and 1 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.17 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or RYTM?

In the previous week, Moderna had 31 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 32 mentions for Moderna and 1 mentions for Rhythm Pharmaceuticals. Moderna's average media sentiment score of 0.47 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 14 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RYTM or VTRS?

In the previous week, Viatris had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 1 mentions for Rhythm Pharmaceuticals. Viatris' average media sentiment score of 0.54 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rhythm Pharmaceuticals (RYTM) Competitors

$86.40 -1.21 (-1.38%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$86.40 +0.00 (+0.01%)

As of 06/5/2026 06:30 PM Eastern

Compare

RYTM vs. BNTX, INSM, ROIV, MRNA, and VTRS

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? MarketBeat compares Rhythm Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rhythm Pharmaceuticals include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Rhythm Pharmaceuticals compare to BioNTech?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

BioNTech has a net margin of -44.39% compared to Rhythm Pharmaceuticals' net margin of -93.33%. BioNTech's return on equity of -5.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, BioNTech had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 1 mentions for Rhythm Pharmaceuticals. BioNTech's average media sentiment score of 0.54 beat Rhythm Pharmaceuticals' score of 0.00 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, suggesting a potential upside of 52.56%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 47.10%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Rhythm Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A
BioNTech	$3.25B	6.86	-$1.29B	-$5.88	N/A

15.5% of BioNTech shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

BioNTech beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Insmed had 20 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 21 mentions for Insmed and 1 mentions for Rhythm Pharmaceuticals. Insmed's average media sentiment score of 0.84 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus price target of $210.50, suggesting a potential upside of 123.41%. Rhythm Pharmaceuticals has a consensus price target of $131.81, suggesting a potential upside of 52.56%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	33.68	-$1.28B	-$5.75	N/A
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A

Summary

Insmed beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A
Roivant Sciences	$8.26M	2,488.71	-$299.77M	-$0.60	N/A

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Roivant Sciences had 10 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 11 mentions for Roivant Sciences and 1 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.17 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Rhythm Pharmaceuticals currently has a consensus target price of $131.81, suggesting a potential upside of 52.56%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 17.53%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Rhythm Pharmaceuticals beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Moderna had 31 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 32 mentions for Moderna and 1 mentions for Rhythm Pharmaceuticals. Moderna's average media sentiment score of 0.47 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	14 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 24.68%. Rhythm Pharmaceuticals has a consensus target price of $131.81, indicating a potential upside of 52.56%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Moderna. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Viatris?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Viatris had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 1 mentions for Rhythm Pharmaceuticals. Viatris' average media sentiment score of 0.54 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Viatris shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A

Viatris has a net margin of -2.04% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Viatris' return on equity of 19.04% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Viatris	-2.04%	19.04%	7.62%

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, indicating a potential upside of 52.56%. Viatris has a consensus target price of $17.50, indicating a potential upside of 10.20%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Rhythm Pharmaceuticals beats Viatris on 9 of the 17 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.92B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.56%
P/E Ratio	-27.60	18.69	24.03	23.62
Price / Sales	31.20	300.26	514.26	110.64
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	41.54	7.97	10.24	6.66
Net Income	-$196.54M	$23.89M	$3.57B	$337.55M
7 Day Performance	-2.17%	-6.96%	-1.28%	-2.52%
1 Month Performance	-10.22%	-2.80%	1.38%	-0.03%
1 Year Performance	26.85%	36.80%	23.93%	25.34%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	2.1519 of 5 stars	$86.40 -1.4%	$131.81 +52.6%	+26.9%	$5.92B	$189.76M	N/A	140	Analyst Forecast
BNTX BioNTech	3.8842 of 5 stars	$91.70 -4.4%	$129.56 +41.3%	-18.8%	$23.19B	$2.81B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7325 of 5 stars	$106.03 -0.8%	$210.95 +99.0%	+28.0%	$23.17B	$606.42M	N/A	1,664	News Coverage Analyst Forecast Insider Trade
ROIV Roivant Sciences	3.1564 of 5 stars	$29.09 -3.0%	$33.59 +15.5%	+154.5%	$21.57B	$8.26M	N/A	860	News Coverage Positive News
MRNA Moderna	1.4133 of 5 stars	$46.06 -2.4%	$35.73 -22.4%	+72.8%	$18.72B	$2.20B	N/A	4,700	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. BNTX, INSM, ROIV, MRNA, and VTRS

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Moderna?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. BNTX, INSM, ROIV, MRNA, and VTRS

How does Rhythm Pharmaceuticals compare to BioNTech?

Is RYTM or BNTX more profitable?

Does the media favor RYTM or BNTX?

Do analysts rate RYTM or BNTX?

Which has preferable valuation and earnings, RYTM or BNTX?

Do institutionals & insiders hold more shares of RYTM or BNTX?

Which has more volatility and risk, RYTM or BNTX?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Does the media prefer INSM or RYTM?

Do analysts recommend INSM or RYTM?

Is INSM or RYTM more profitable?

Which has more volatility and risk, INSM or RYTM?

Which has stronger earnings & valuation, INSM or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Which has preferable valuation and earnings, RYTM or ROIV?

Which has more risk & volatility, RYTM or ROIV?

Do insiders & institutionals hold more shares of RYTM or ROIV?

Does the media refer more to RYTM or ROIV?

Is RYTM or ROIV more profitable?

Do analysts rate RYTM or ROIV?

Summary

How does Rhythm Pharmaceuticals compare to Moderna?

Does the media favor MRNA or RYTM?

Do analysts prefer MRNA or RYTM?

Which has preferable earnings and valuation, MRNA or RYTM?

Is MRNA or RYTM more profitable?

Do insiders & institutionals have more ownership in MRNA or RYTM?

Which has more risk and volatility, MRNA or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Does the media refer more to RYTM or VTRS?

Do institutionals and insiders believe in RYTM or VTRS?

Which has higher earnings and valuation, RYTM or VTRS?

Is RYTM or VTRS more profitable?

Which has more volatility and risk, RYTM or VTRS?

Do analysts prefer RYTM or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools